search
Back to results

Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care) (IVOIRE)

Primary Purpose

Shock, Septic, Renal Failure, Acute

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Venovenous haemofiltration (renal replacement therapy)
Venovenous haemofiltration (renal replacement therapy)
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Shock, Septic focused on measuring Shock, Septic, Renal Failure, Acute, Venovenous Hemofiltration, Randomized Controlled Trial, Multicenter Study, Mortality

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: septic shock (Bone criteria) for less than 24 hours RIFLE criteria : injury or worse age over 18 years written informed consent by next of kin. Exclusion Criteria: cirrhosis age over 80 years life expectancy less than 3 months or metastatic cancer for women : pregnancy and breastfeeding

Sites / Locations

  • Astrid Queen Military Hospital
  • Cliniques de l'Europe
  • TIVOLI Hospital
  • University Hospital
  • St-Pierre Para-University Hospital
  • Hospital
  • Clinic Bordeaux Nord
  • University Hospital
  • University Hospital
  • Hospital R Boulin - Libourne
  • University Hospital
  • Aphp - Hegp
  • Service d'Anesthésie-Réanimation II, Groupe Hospitalier Sud, CHU de Bordeaux
  • Hospital
  • Hospital
  • Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

High Volume

Medium Volume

Arm Description

ultra filtration : High volume : 70 ml/kg/h

Ultra filtration : conventional volume : 35 ml/kg/h

Outcomes

Primary Outcome Measures

all-cause mortality.

Secondary Outcome Measures

Haemodynamic parameters and volume loading
Doses and duration of catecholamine infusions
Organ failures
Duration of mechanical ventilation
Duration of renal replacement therapy
Morbidity
Length of stay in ICU and hospital
Mortality

Full Information

First Posted
October 17, 2005
Last Updated
October 12, 2010
Sponsor
University Hospital, Bordeaux
Collaborators
Ministry of Health, France
search

1. Study Identification

Unique Protocol Identification Number
NCT00241228
Brief Title
Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)
Acronym
IVOIRE
Official Title
Impact of High-volume Veno-venous Continuous Hemofiltration in the Early Management of Septic Shock Patients With Acute Renal Failure
Study Type
Interventional

2. Study Status

Record Verification Date
October 2010
Overall Recruitment Status
Completed
Study Start Date
October 2005 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
October 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University Hospital, Bordeaux
Collaborators
Ministry of Health, France

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Sepsis and septic shock are still important causes of mortality in intensive care medicine. Renal replacement therapy by standard volume haemofiltration is currently used, but a higher-volume haemofiltration may improve the prognosis. The study is a prospective randomized multicenter trial comparing two treatments in patients suffering from septic shock complicated with acute renal failure admitted to ICU. One group will be treated by early high volume haemofiltration (70 ml/kg/h) and the second group by standard volume haemofiltration (35 ml/kg/h). The main outcome will be one-month mortality.
Detailed Description
Background Sepsis and septic shock are still important causes of mortality in intensive care medicine nowadays. Mortality ranges from 40 up to 80 % depending on the number of organ failures. Therapeutic strategy consists of two major components: haemodynamic stabilization with restoration of adequate arterial pressure and optimization of peripheral perfusion delivery, and infection treatment. Mortality remains high despite the use of new antimicrobial therapy and adjuvant therapies such as activated protein C, low dose corticoids and haemofiltration. Initial observations in patients with acute renal failure treated by haemofiltration showed azotemia control, restoration of the sodium-water balance, elimination of inflammatory mediators and improvement of the cardiac and pulmonary functions was demonstrated independently of a negative water balance. There is no human randomized study so far demonstrating these preliminary findings. Nevertheless, several authors have demonstrated inflammatory mediators elimination by the use of haemofiltration. Moreover, the clinical improvement seems to be related to the ultra filtration dose and to the early initiation of therapy. Joannes-Boyau et al carried out a pilot study in abdominal surgery patients demonstrating that the use of high volume haemofiltration in patients with septic shock and multiple organ failure restores hemodynamic stability with drastic reductions in catecholamine requirements and a substantial reduction of observed vs. expected mortality. Objectives The principal objective of the study is to evaluate the effect of early Continuous High Volume Haemofiltration on 28-day mortality in patients with septic shock complicated by acute renal failure. The secondary objectives are to assess the effect of High Volume Haemofiltration on haemodynamics, doses of catecholamines, organ failures, duration of mechanical ventilation, duration of renal replacement therapy need, morbidity, length of ICU and hospital stay, and 60- and 90-day mortality. Study design Open label randomized multicenter controlled trial on two parallel groups of patients with septic shock and acute renal failure admitted to ICU, treated early either by high volume (70 ml/kg/h) or by standard volume (35 ml/kg/h) haemofiltration. Eligibility criteria Inclusion criteria. Septic shock (Bone criteria) for less than 24 hours, RIFLE criteria : injury or worse, age over 18 years, and written informed consent by next of kin. Non inclusion criteria. Cirrhosis, age over 80 years, life expectancy less than 3 months or metastatic cancer. Intervention High volume (70 ml/kg/h) vs. standard volume (35 ml/kg/h) haemofiltration during 96 hours. Further renal replacement therapy (if haemofiltration, only standard volume is allowed) may be used according to investigator decision. Primary endpoint All cause 28-day mortality. Statistical aspects 460 patients are planned to be included (230 in each group). A 15 % absolute reduction in 28-days all-cause mortality in the high volume group compared with the standard group is expected. However, as this reduction might be greater, an interim analysis is planned when half of the total sample size will have been included. Data will be analyzed on an intention-to-treat basis. Duration of the study: 3 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Shock, Septic, Renal Failure, Acute
Keywords
Shock, Septic, Renal Failure, Acute, Venovenous Hemofiltration, Randomized Controlled Trial, Multicenter Study, Mortality

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
139 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High Volume
Arm Type
Experimental
Arm Description
ultra filtration : High volume : 70 ml/kg/h
Arm Title
Medium Volume
Arm Type
Active Comparator
Arm Description
Ultra filtration : conventional volume : 35 ml/kg/h
Intervention Type
Device
Intervention Name(s)
Venovenous haemofiltration (renal replacement therapy)
Intervention Description
High Volume ultra filtration (70 ml/kg/h)
Intervention Type
Device
Intervention Name(s)
Venovenous haemofiltration (renal replacement therapy)
Intervention Description
Conventional Volume (35 ml/kg/h)
Primary Outcome Measure Information:
Title
all-cause mortality.
Time Frame
28-day
Secondary Outcome Measure Information:
Title
Haemodynamic parameters and volume loading
Time Frame
Every 12 hours during 96 hours after inclusion
Title
Doses and duration of catecholamine infusions
Time Frame
Every 12 hours during 96 hours after inclusion
Title
Organ failures
Time Frame
During 96 hours after inclusion
Title
Duration of mechanical ventilation
Time Frame
Total during the stay in intensive care
Title
Duration of renal replacement therapy
Time Frame
Total during the stay in Intensive Care Unity (ICU)
Title
Morbidity
Time Frame
Total during the stay in intensive care
Title
Length of stay in ICU and hospital
Time Frame
End of hospitalization
Title
Mortality
Time Frame
in ICU (96 first hours after inclusion), 60 and 90-day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: septic shock (Bone criteria) for less than 24 hours RIFLE criteria : injury or worse age over 18 years written informed consent by next of kin. Exclusion Criteria: cirrhosis age over 80 years life expectancy less than 3 months or metastatic cancer for women : pregnancy and breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olivier JOANNES-BOYAU, Dr
Organizational Affiliation
University Hospital, Bordeaux, France
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Patrick HONORE, Dr
Organizational Affiliation
Quuen Astrid Military Hospital, BRUXELLES - Belgium
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Paul Perez, Dr
Organizational Affiliation
University Hospital, Bordeaux, France
Official's Role
Study Chair
Facility Information:
Facility Name
Astrid Queen Military Hospital
City
Bruxelles (Neder Over Hembeek)
Country
Belgium
Facility Name
Cliniques de l'Europe
City
Bruxelles
Country
Belgium
Facility Name
TIVOLI Hospital
City
La Louviere
Country
Belgium
Facility Name
University Hospital
City
Liege
Country
Belgium
Facility Name
St-Pierre Para-University Hospital
City
Ottignies-Louvain-La-Neuve
Country
Belgium
Facility Name
Hospital
City
Agen
ZIP/Postal Code
47923
Country
France
Facility Name
Clinic Bordeaux Nord
City
Bordeaux
ZIP/Postal Code
33077
Country
France
Facility Name
University Hospital
City
Brest
ZIP/Postal Code
29200
Country
France
Facility Name
University Hospital
City
Grenoble
ZIP/Postal Code
38600
Country
France
Facility Name
Hospital R Boulin - Libourne
City
Libourne
ZIP/Postal Code
33505
Country
France
Facility Name
University Hospital
City
Lyon
ZIP/Postal Code
69317
Country
France
Facility Name
Aphp - Hegp
City
Paris
ZIP/Postal Code
75908
Country
France
Facility Name
Service d'Anesthésie-Réanimation II, Groupe Hospitalier Sud, CHU de Bordeaux
City
Pessac
ZIP/Postal Code
33604
Country
France
Facility Name
Hospital
City
Tourcoing
ZIP/Postal Code
59209
Country
France
Facility Name
Hospital
City
Delf
Country
Netherlands
Facility Name
Hospital
City
Heerlen
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
23740278
Citation
Joannes-Boyau O, Honore PM, Perez P, Bagshaw SM, Grand H, Canivet JL, Dewitte A, Flamens C, Pujol W, Grandoulier AS, Fleureau C, Jacobs R, Broux C, Floch H, Branchard O, Franck S, Roze H, Collin V, Boer W, Calderon J, Gauche B, Spapen HD, Janvier G, Ouattara A. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013 Sep;39(9):1535-46. doi: 10.1007/s00134-013-2967-z. Epub 2013 Jun 6.
Results Reference
derived

Learn more about this trial

Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)

We'll reach out to this number within 24 hrs